keyword
MENU ▼
Read by QxMD icon Read
search

Memantine

keyword
https://www.readbyqxmd.com/read/29771687/memantine-er-maintains-patient-response-in-moderate-to-severe-alzheimer-s-disease-post-hoc-analyses-from-a-randomized-controlled-clinical-trial-of-patients-treated-with-cholinesterase-inhibitors
#1
George T Grossberg, Gustavo Alva, Suzanne Hendrix, Noel Ellison, Mary C Kane, John Edwards
Memantine extended release (ER) significantly outperformed placebo on co-primary endpoints of Clinician's Interview-based Impression of Change Plus Caregiver Input (CIBIC-Plus) and baseline to endpoint changes on the Severe Impairment Battery (SIB) in a 24-week, randomized trial (NCT00322153) in patients with moderate to severe Alzheimer's disease taking a cholinesterase inhibitor (ChEI). A post hoc analysis compared patients receiving memantine ER/ChEI to placebo/ChEI for time to onset of response and if the response was maintained (achieving improvement at weeks 8, 12, or 18 and maintaining through endpoint/week 24) on the SIB, the Neuropsychiatric Inventory (NPI), CIBIC-Plus, and Activities of Daily Living (ADL) using Fisher exact test...
May 16, 2018: Alzheimer Disease and Associated Disorders
https://www.readbyqxmd.com/read/29768996/a-systematic-review-on-donepezil-based-derivatives-as-potential-cholinesterase-inhibitors-for-alzheimer-s-disease
#2
Jan Korabecny, Katarina Spilovska, Eva Mezeiova, Ondrej Benek, Radomir Juza, Daniel Kaping, Ondrej Soukup
Alzheimer's disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach has been approved for the treatment of AD. The pharmacotherapy of AD has relied on non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase (AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine...
May 16, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29767953/pharmacological-and-electrophysiological-characterization-of-novel-nmda-receptor-antagonists
#3
Rosana Leiva, Matthew B Phillips, Andreea Larisa Turcu, Esther Gratacòs-Batlle, Lara León-García, Francesc X Sureda, David Soto, Jon W Johnson, Santiago Vazquez
This work reports the synthesis, and pharmacological and electrophysiological evaluation of new N-methyl-D-aspartic acid receptor (NMDAR) channel blocking antagonists featuring polycyclic scaffolds. Changes in the chemical structure modulate the potency and voltage dependence of inhibition. Two of the new antagonists display properties comparable to those of memantine, a clinically approved NMDAR antagonist.
May 16, 2018: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/29762677/anti-dementia-drugs-for-psychopathology-and-cognitive-impairment-in-schizophrenia-a-systematic-review-and-meta-analysis
#4
Taro Kishi, Toshikazu Ikuta, Kazuto Oya, Shinji Matsunaga, Yuki Matsuda, Nakao Iwata
Background: We conducted a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials of anti-dementia drugs plus antipsychotics (ADD+AP) for schizophrenia. Methods: Primary outcomes of efficacy and safety included improving overall symptoms (Positive and Negative Syndrome Scale and Brief Psychiatric Rating Scale scores) and all-cause discontinuation, respectively. Other outcomes included psychopathology subscales (positive, negative, general, and anxiety/depressive symptoms), cognitive function (attention/vigilance, reasoning/problem solving, social cognition, speed of processing, verbal learning, visual learning, working memory, and cognitive control/executive function), Mini-Mental State Examination (MMSE) scores, treatment discontinuation due to adverse events and inefficacy, and individual adverse events...
May 14, 2018: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29751937/beyond-thiamine-treatment-for-cognitive-impairment-in-korsakoff-s-syndrome
#5
REVIEW
Justin M Johnson, Valerie Fox
BACKGROUND: Wernicke's encephalopathy is a condition whose treatment many consultation-liaison psychiatrists know quite well. Less clear, however, is the treatment of its dementia disorder descendent, the Korsakoff's syndrome (KS). OBJECTIVE: This article seeks to review treatment options and provide recommendations for consultation-liaison psychiatrists treating cognitive impairment in KS. METHODS: In this nonsystematic review, we reviewed PubMed, CINAHL Plus, and Google Scholar for published reports and studies regarding treatment of KS...
March 27, 2018: Psychosomatics
https://www.readbyqxmd.com/read/29742912/the-impact-of-a-long-term-rivastigmine-and-donepezil-treatment-on-all-cause-mortality-in-patients-with-alzheimer-s-disease
#6
Jakub Kazmierski, Chaido Messini-Zachou, Mara Gkioka, Magda Tsolaki
Cholinesterase inhibitors (ChEIs) are the mainstays of symptomatic treatment of Alzheimer's disease (AD); however, their efficacy is limited, and their use was associated with deaths in some groups of patients. The aim of the current study was to assess the impact of the long-term use of ChEIs on mortality in patients with AD. This observational, longitudinal study included 1171 adult patients with a diagnosis of AD treated with donepezil or rivastigmine. Each patient was observed for 24 months or until death...
January 1, 2018: American Journal of Alzheimer's Disease and Other Dementias
https://www.readbyqxmd.com/read/29742314/benzofuran-and-indole-a-promising-scaffold-for-drug-development-in-alzheimer-s-disease
#7
Deepti Goyal, Amandeep Kaur, Bhupesh Goyal
Alzheimer's disease (AD) is a progressive neurodegenerative disease with no clinically accepted treatment to cure or halt its progression. The Food and Drug Administration (FDA) approved drugs (rivastigmine, donepezil, galantamine and memantine) at best provide marginal benefits thus emphasize the urgent need to explore other molecular entities as future drug candidates for AD. Looking at the wide pharmaceutical applications of heterocyclic compounds and particularly those containing benzofuran and indole ring system; these molecular frameworks draw special attention of the medicinal chemists for further evaluation in numerous diseases...
May 9, 2018: ChemMedChem
https://www.readbyqxmd.com/read/29734182/a-systematic-review-and-meta-analysis-of-the-effectiveness-of-acetylcholinesterase-inhibitors-and-memantine-in-treating-the-cognitive-symptoms-of-dementia
#8
Ruth Knight, Mizanur Khondoker, Nicholas Magill, Robert Stewart, Sabine Landau
BACKGROUND: Acetylcholinesterase inhibitors (AChEIs) and memantine are commonly used in the management of dementia. In routine clinical practice, dementia is often monitored via the Mini-Mental State Examination (MMSE). We conducted a systematic review and meta-analysis of the effects of these drugs on MMSE scores. SUMMARY: Eighty trials were identified. Pooled effect estimates were in favour of both AChEIs and memantine at 6 months. Meta-regression indicated that dementia subtype was a moderator of AChEI treatment effect, with the effect of treatment versus control twice as high for patients with Parkinson disease dementia/ dementia with Lewy bodies (2...
May 7, 2018: Dementia and Geriatric Cognitive Disorders
https://www.readbyqxmd.com/read/29732929/drug-development-for-alzheimer-s-disease-review
#9
Kejing Lao, Naichun Ji, Xiaohua Zhang, Wenwei Qiao, Zhishu Tang, Xingchun Gou
Alzheimer's disease (AD) is a chronic neurodegenerative disease, which is considered one of the most intractable medical problems with heavy social and economic costs. The current drugs for AD, including acetylcholinesterase inhibitors (AChEIs) and memantine, a NMDA receptor antagonist, only temporarily ameliorate cognitive decline, but are unable to stop or reverse the progression of dementia. This paper reviewed the recent advance in AD drug development. The drug discovery programs under clinical trials targeting cholinergic system, α7 nicotinic acetylcholine receptors (nAChRs), N-methyl-D-aspartate receptor (NMDAR), β-secretase, γ-secretase modulators, tau, inflammatory mediators and glucagon-like peptide-1 (GLP-1) were discussed...
May 7, 2018: Journal of Drug Targeting
https://www.readbyqxmd.com/read/29732913/augmentation-strategies-for-clozapine-refractory-schizophrenia-a-systematic-review-and-meta-analysis
#10
Dan J Siskind, Michael Lee, Arul Ravindran, Qichen Zhang, Evelyn Ma, Balaji Motamarri, Steve Kisely
BACKGROUND: Although clozapine is the most effective medication for treatment refractory schizophrenia, only 40% of people will meet response criteria. We therefore undertook a systematic review and meta-analysis of global literature on clozapine augmentation strategies. METHODS: We systematically reviewed PubMed, PsycInfo, Embase, Cochrane Database, Chinese Biomedical Literature Service System and China Knowledge Resource Integrated Database for randomised control trials of augmentation strategies for clozapine resistant schizophrenia...
May 1, 2018: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/29729893/memantine-ameliorates-depressive-like-behaviors-by-regulating-hippocampal-cell-proliferation-and-neuroprotection-in-olfactory-bulbectomized-mice
#11
Kohei Takahashi, Osamu Nakagawasai, Wataru Nemoto, Shogo Kadota, Jinichi Isono, Takayo Odaira, Wakana Sakuma, Yuichiro Arai, Takeshi Tadano, Koichi Tan-No
Our previous study suggested that the non-competitive N-methyl-d-aspartate receptor antagonist memantine (MEM) inhibits dopamine (DA) reuptake and turnover by inhibiting brain monoamine oxidase. Clinical studies have reported that MEM may improve depressive symptoms; however, specific mechanisms underlying this effect are unclear. We performed emotional behavior, tail suspension, and forced swimming tests to examine whether MEM has antidepressant effects in olfactory bulbectomized (OBX) mice, an animal model of depression...
May 3, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29727890/-therapy-of-dementia-state-of-the-art
#12
Benjamin Roeben, Tania Zieschang, Walter Maetzler
Due to the aging population, dementias represent a growing challenge for the health systems and for the society. This overview summarizes the current state of already practice-relevant therapies and management of dementias. Non-pharmacological approaches have a greater impact than pharmacological treatment. Increasing evidence underlines that consistent management of cardiovascular risk factors has beneficial effects on the progression of at least some, possibly almost all types of dementias. The main pharmacological agents for symptomatic treatment of cognitive deficits in Alzheimer's and Parkinson's disease-associated dementias are cholinesterase inhibitors and memantine...
May 2018: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29717478/monotherapy-is-good-enough-for-patients-with-mild-to-moderate-alzheimer-s-disease-a-network-meta-analysis-of-76-randomized-controlled-trials
#13
Kelvin Kf Tsoi, Joyce Yc Chan, Felix Ch Chan, Hoyee W Hirai, Timothy Cy Kwok, Samuel Ys Wong
Memantine and the Acetylcholinesterase inhibitors (AChEIs) are two classes of drugs that are used to treat patients with Alzheimer's disease. We conducted a network meta-analysis of randomized controlled trials to compare the treatment effectiveness of monotherapy or combination therapy A total of 23,707 AD patients in 76 randomized trials were identified. In patients with mild-to-moderate AD, monotherapy with donepezil, galantamine or rivastigmine were superior to placebo in enhancing cognitive functions and activities of daily living (ADL), whereas monotherapy with donepezil or memantine were superior to placebo in improving behavioral symptoms...
May 1, 2018: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29710726/effectiveness-of-anti-dementia-drugs-in-extremely-severe-alzheimer-s-disease-a-12-week-multicenter-randomized-single-blind-study
#14
Yun Jeong Hong, Seong Hye Choi, Jee Hyang Jeong, Kyung Won Park, Hae Ri Na
BACKGROUND/OBJECTIVE: There is insufficient evidence to guide decisions concerning how long anti-dementia drug (ADD) regimens should be maintained in severe Alzheimer's disease (AD). We investigated whether patients with extremely severe AD who were already receiving donepezil or memantine benefited from continuing treatment. METHODS: In this randomized and rater-blinded trial, 65 AD patients with a Mini-Mental State Examination score from 0 to 5 and a score of 6c or worse on Functional Assessment Staging were randomly assigned to an ADD-continuation group (N = 30) or an ADD-discontinuation group (N = 35)...
April 28, 2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29697715/catatonia-in-the-medically-ill-etiology-diagnosis-and-treatment-the-academy-of-consultation-liaison-psychiatry-evidence-based-medicine-subcommittee-monograph
#15
Lex Denysenko, Nicole Sica, Thomas M Penders, Kemuel L Philbrick, Audrey Walker, Scott Shaffer, Paula Zimbrean, Oliver Freudenreich, Nicole Rex, Brendan T Carroll, Andrew Francis
BACKGROUND: Catatonia in medically ill patients is rare but often unrecognized. This monograph summarizes current knowledge on the diagnosis, epidemiology, etiology, and management of catatonia occurring in the medical setting. METHODS: PubMed searches were used to identify relevant articles from 1962 to present. RESULTS: More than 3,000 articles were obtained and reviewed for relevance, including references of articles identified by the initial search...
May 2018: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/29695962/inhibition-of-nmda-receptors-prevents-the-loss-of-bdnf-function-induced-by-amyloid-%C3%AE
#16
Sara R Tanqueiro, Rita M Ramalho, Tiago M Rodrigues, Luísa V Lopes, Ana M Sebastião, Maria J Diógenes
Brain-derived neurotrophic factor (BDNF) plays important functions in cell survival and differentiation, neuronal outgrowth and plasticity. In Alzheimer's disease (AD), BDNF signaling is known to be impaired, partially because amyloid β (Aβ) induces truncation of BDNF main receptor, TrkB-full length (TrkB-FL). We have previously shown that such truncation is mediated by calpains, results in the formation of an intracellular domain (ICD) fragment and causes BDNF loss of function. Since calpains are Ca2+ -dependent proteases, we hypothesized that excessive intracellular Ca2+ build-up could be due to dysfunctional N-methyl-d-aspartate receptors (NMDARs) activation...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29682419/inducible-nitric-oxide-synthase-nos2-knockout-mice-as-a-model-of-trichotillomania
#17
Plinio C Casarotto, Caroline Biojone, Karina Montezuma, Fernando Q Cunha, Samia R L Joca, Eero Castren, Francisco S Guimaraes
Background: Trichotillomania (TTM) is an impulse control disorder characterized by repetitive hair pulling/trimming. Barbering behavior (BB) observed in laboratory animals is proposed as a model of TTM. The neurobiological basis of TTM is unclear, but involves striatal hyperactivity and hypoactivation of the prefrontal cortex. Methods: In this study, we evaluated the BB in knockout mice for the inducible isoform of nitric oxide synthase (NOS2KO) and the consequences of silencing this enzyme in PC12 cell differentiation...
2018: PeerJ
https://www.readbyqxmd.com/read/29680698/effectiveness-of-memantine-on-depression-like-behavior-memory-deficits-and-brain-mrna-levels-of-bdnf-and-trkb-in-rats-subjected-to-repeated-unpredictable-stress
#18
Meysam Amidfar, Yong-Ku Kim, Ove Wiborg
BACKGROUND: Previous clinical and preclinical studies have indicated that the N-methyl-d-aspartate (NMDA) receptor antagonist, memantine, has neuroprotective properties as well as antidepressant effects. The present study was designed to examine behavioral and molecular effects of memantine administration in rats subjected to the repeated unpredictable stress (RUS) paradigm. METHODS: Rats were split into four groups at random including control + saline, control + memantine, stressed + saline and stressed + memantine...
December 20, 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/29670547/medications-used-for-cognitive-enhancement-in-patients-with-schizophrenia-bipolar-disorder-alzheimer-s-disease-and-parkinson-s-disease
#19
REVIEW
Wen-Yu Hsu, Hsien-Yuan Lane, Chieh-Hsin Lin
Background/aims: Cognitive impairment, which frequently occurs in patients with schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease, has a significant impact on the daily lives of both patients and their family. Furthermore, since the medications used for cognitive enhancement have limited efficacy, the issue of cognitive enhancement still remains a clinically unsolved challenge. Sampling and methods: We reviewed the clinical studies (published between 2007 and 2017) that focused on the efficacy of medications used for enhancing cognition in patients with schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease...
2018: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29670280/mechanism-of-nmda-receptor-channel-block-by-mk-801-and-memantine
#20
Xianqiang Song, Morten Ø Jensen, Vishwanath Jogini, Richard A Stein, Chia-Hsueh Lee, Hassane S Mchaourab, David E Shaw, Eric Gouaux
The NMDA (N-methyl-D-aspartate) receptor transduces the binding of glutamate and glycine, coupling it to the opening of a calcium-permeable ion channel 1 . Owing to the lack of high-resolution structural studies of the NMDA receptor, the mechanism by which ion-channel blockers occlude ion permeation is not well understood. Here we show that removal of the amino-terminal domains from the GluN1-GluN2B NMDA receptor yields a functional receptor and crystals with good diffraction properties, allowing us to map the binding site of the NMDA receptor blocker, MK-801...
April 18, 2018: Nature
keyword
keyword
27860
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"